Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Ottawa

$45,000.00

The role of the transcriptional co-repressor RIP 140 in muscular dystrophy: a therapeutic target?

FY 2011-12

Summary
Duchenne Muscular Dystrophy (DMD) is the most prevalent inherited neuromuscular disorder. This disease is extremely severe as children become wheelchair-bound by early adolescence and death occurs in their second or third decade of life. DMD results from mutations/deletions in the dystrophin gene which prevents production of the dystrophin protein. A therapeutic strategy consists of utilizing a protein normally expressed in dystrophic muscle which, once expressed at appropriate levels and at the correct location, could functionally compensate for the lack of dystrophin. A candidate for such a role is utrophin. It has been demonstrated that increasing the abundance of slow-twitch muscle fibers, which have an abundance of utrophin, can reduce the severity of DMD. The muscle protein RIP 140 has recently been discovered to reduce the expression of slow-twitch muscle fibers in animals. However, the role that this protein plays in DMD is unknown. Thus, the purpose of this proposal is to determine the role of RIP 140 in the pathology of DMD. This study tests the hypothesis that RIP 140 represses the expression of slow-twitch muscle fibers, and consequently utrophin, and thus exacerbates the pathology of DMD. To test this hypothesis, we will employ a measured and systematic approach to determine 1) the expression and localization patterns of RIP 140 in dystrophic muscle, 2) the function that this protein plays in dystrophic muscle, and 3) the direct influence RIP 140 has on regulating utrophin expression. These pre-clinical studies will be executed with commonly-used and experimentally-validated cell tissue culture and animal models of DMD, as well as a targeted array of physiologic, biochemical and molecular analyses. The results from this proposal will shed new light on the molecular mechanisms of DMD pathology, and may reveal a novel therapeutic target in RIP 140 for future lifestyle and pharmacological interventions designed to contest this unrelenting disease.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
242418
Name
Ljubicic Vladimir
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of the transcriptional co-repressor RIP 140 in muscular dystrophy: a therapeutic target?
Programtype2
Fellowship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Duchenne Muscular Dystrophy; Gene Expression; Mdx Mice; Pgc-1 Alpha; Plasticity; Ppar Delta; Rip 140; Skeletal Muscle; Therapeutic Target; Utrophin
Abstract
Duchenne Muscular Dystrophy (DMD) is the most prevalent inherited neuromuscular disorder. This disease is extremely severe as children become wheelchair-bound by early adolescence and death occurs in their second or third decade of life. DMD results from mutations/deletions in the dystrophin gene which prevents production of the dystrophin protein. A therapeutic strategy consists of utilizing a protein normally expressed in dystrophic muscle which, once expressed at appropriate levels and at the correct location, could functionally compensate for the lack of dystrophin. A candidate for such a role is utrophin. It has been demonstrated that increasing the abundance of slow-twitch muscle fibers, which have an abundance of utrophin, can reduce the severity of DMD. The muscle protein RIP 140 has recently been discovered to reduce the expression of slow-twitch muscle fibers in animals. However, the role that this protein plays in DMD is unknown. Thus, the purpose of this proposal is to determine the role of RIP 140 in the pathology of DMD. This study tests the hypothesis that RIP 140 represses the expression of slow-twitch muscle fibers, and consequently utrophin, and thus exacerbates the pathology of DMD. To test this hypothesis, we will employ a measured and systematic approach to determine 1) the expression and localization patterns of RIP 140 in dystrophic muscle, 2) the function that this protein plays in dystrophic muscle, and 3) the direct influence RIP 140 has on regulating utrophin expression. These pre-clinical studies will be executed with commonly-used and experimentally-validated cell tissue culture and animal models of DMD, as well as a targeted array of physiologic, biochemical and molecular analyses. The results from this proposal will shed new light on the molecular mechanisms of DMD pathology, and may reveal a novel therapeutic target in RIP 140 for future lifestyle and pharmacological interventions designed to contest this unrelenting disease.
Competitiondate
201110
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ljubicic, Vladimir
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $45,000~ $0~